Neurogenic locus notch homolog protein 2 (NOTCH2) (NOTCH2)

Neurogenic locus notch homolog protein 2 (NOTCH2) is a critical type I transmembrane receptor that functions as a key mediator in the highly conserved Notch signaling pathway, which regulates cell-to-cell communication and developmental patterning [UniProt P24033]. The NOTCH2 mRNA encodes a protein that, upon activation by ligands such as Jagged or Delta-like, undergoes sequential proteolytic cleavages, the last of which is mediated by the gamma-secretase complex, releasing the Notch intracellular domain (NICD2) [NCBI Gene 4853]. This domain translocates to the nucleus where it acts as a transcriptional activator for target genes involved in cell fate determination, proliferation, and apoptosis. NOTCH2 is uniquely essential for the maturation of marginal zone B-cells and plays significant roles in liver and skeletal development [PubMed 21376303]. Pathologically, gain-of-function mutations or overexpression of NOTCH2 are frequently observed in B-cell malignancies and various solid tumors, while germline mutations are linked to Alagille syndrome and Hajdu-Cheney syndrome [PubMed 23918255]. Therapeutic strategies include monoclonal antibodies like Tarextumab that block ligand binding and small-molecule gamma-secretase inhibitors, with emerging research into mRNA-targeting approaches to achieve isoform-specific modulation and reduce the systemic toxicities associated with pan-Notch inhibition [ClinicalTrials.gov NCT01277133].

Other names

Notch 2hN2Alagille syndrome 2AGS2Hajdu-Cheney syndromeHJCYS

Inhibition of the Notch signaling pathway by blocking ligand binding to the extracellular domain, preventing proteolytic cleavage by the gamma-secretase complex, or potentially through mRNA degradation using antisense oligonucleotides or siRNA to reduce receptor expression.